Form 4: Lexeo Therapeutics CEO Acquires Additional Shares Through Employee Stock Purchase Plan

Richard Nolan Townsend, CEO of Lexeo Therapeutics, reports the acquisition of 2,128 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• Richard Nolan Townsend, the CEO of Lexeo Therapeutics, has reported a transaction involving the company's common stock.
• On March 14, 2025, Townsend acquired 2,128 shares of Lexeo Therapeutics common stock.
• The acquisition was made through the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan at a price of $2.61 per share.
• Following this transaction, Townsend directly owns 222,247 shares of Lexeo Therapeutics common stock.
• The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan.
• This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine transaction. The CEO's participation in the employee stock purchase plan is a mildly positive signal, but not significantly impactful.

Positives

• The CEO's participation in the Employee Stock Purchase Plan could be seen as a positive signal, indicating confidence in the company's future.

Industry Context

This filing is a routine disclosure related to insider trading regulations. It provides transparency into the transactions of company insiders, allowing investors to monitor their activity and potential alignment with company performance.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the CEO's increased investment in the company.

Key Dates

Keywords

Lexeo Therapeutics, Richard Nolan Townsend, CEO, Employee Stock Purchase Plan, Common Stock, LXEO, Beneficial Ownership, SEC Form 4